Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients
- 25 June 2008
- journal article
- clinical trial
- Published by Wiley in Movement Disorders
- Vol. 23 (11) , 1532-1540
Abstract
The effects of rivastigmine versus placebo in Parkinson's disease dementia (PDD) patients with elevated or normal/low plasma homocysteine were determined. In this prospective analysis of a 24‐week, randomly assigned, placebo‐controlled study of rivastigmine in PDD, subpopulations comprised patients with plasma homocysteine ≥14 μmol/L (elevated) or P < 0.01), and significant treatment differences on secondary outcomes. Rivastigmine‐ and placebo‐treated hyperhomocysteinemic patients (16.5% and 14.6%) discontinued the study because of AEs. Patients with normal/low homocysteine showed no treatment differences on primary or secondary outcomes (1.4 on the ADAS‐cog and 0.1 on ADCS‐CGIC, both P = ns); 16.7% and 10.3% rivastigmine‐ and placebo‐treated patients discontinued because of AEs. Elevated homocysteine was associated with greater rivastigmine treatment differences than normal/low homocysteine. © 2008 Movement Disorder SocietyKeywords
This publication has 31 references indexed in Scilit:
- Hyperhomocysteinemia and Venous ThrombosisSeminars in Hematology, 2007
- Cardiac safety of rivastigmine in Lewy body and Parkinson's disease dementiasInternational Journal Of Clinical Practice, 2006
- Homocysteine and Cognitive Performance in the Framingham Offspring Study: Age Is ImportantAmerican Journal of Epidemiology, 2005
- Homocysteine and B vitamins in mild cognitive impairment and dementiaClinical Chemistry and Laboratory Medicine (CCLM), 2005
- Rationale for current therapies in Parkinson’s diseaseExpert Opinion on Pharmacotherapy, 2003
- Neurobiology of butyrylcholinesteraseNature Reviews Neuroscience, 2003
- Plasma Homocysteine as a Risk Factor for Dementia and Alzheimer's DiseaseNew England Journal of Medicine, 2002
- Rivastigmine, a Brain-Selective Acetylcholinesterase Inhibitor, Ameliorates Cognitive and Motor Deficits Induced by Closed-Head Injury in the MouseJournal of Neurotrauma, 1998
- Post-ischemic administration of the acetylcholinesterase inhibitor ENA-713 prevents delayed neuronal death in the gerbil hippocampusNeurochemical Research, 1995
- “Mini-mental state”Journal of Psychiatric Research, 1975